This content is from: Premium

These Hedge Funds May Profit From BridgeBio IPO

Viking Global Investors is among the principal shareholders named in BridgeBio’s IPO prospectus.

Viking Global Investors and Perceptive Advisors stand to benefit from the planned initial public offering of BridgeBio Pharma, a drug company in Palo, Alto California that was founded in 2015.Hedge fund firm Viking Global Investors and KKR & Co. each own at least five percent of its shares, according to a

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content